Mode of action of mood stabilizers: is the arachidonic acid cascade a common target? (Q34762525)

4 August 2017

1 reference

title

Mode of action of mood stabilizers: is the arachidonic acid cascade a common target? (English)

1 reference

4 August 2017

J S Rao

1

1 reference

4 August 2017

H-J Lee

series ordinal

2

1 reference

4 August 2017

S I Rapoport

series ordinal

3

1 reference

4 August 2017

R P Bazinet

series ordinal

4

1 reference

4 August 2017

language of work or name

English

0 references

publication date

18 March 2008

1 reference

4 August 2017

1 reference

4 August 2017

13

1 reference

4 August 2017

6

1 reference

4 August 2017

585-596

1 reference

https://scigraph.springernature.com/pub.10.1038/mp.2008.31

4 August 2017

0 references

cites work

Bipolar II disorder : epidemiology, diagnosis and management

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Desmopressin for nocturnal enuresis in nephrogenic diabetes insipidus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Affective Disorders and Suicide Risk: A Reexamination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Mood disorders in the medically ill: scientific review and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Costs of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Search for a common mechanism of mood stabilizers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Comparison of lithium concentrations in red blood cells and plasma in samples collected for TDM, acute toxicity, or acute-on-chronic toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Does carbamazepine have a narrow therapeutic plasma concentration range?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

A comprehensive classification system for lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Lithium decreases turnover of arachidonate in several brain phospholipids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

85 kDa cytosolic phospholipase A2 is a target for chronic lithium in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Neural and developmental actions of lithium: a unifying hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Signaling networks in the pathophysiology and treatment of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

In vivo conversion of linoleic acid to arachidonic acid in human adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Brain elongation of linoleic acid is a negligible source of the arachidonate in brain phospholipids of adult rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Upregulated liver conversion of alpha-linolenic acid to docosahexaenoic acid in rats on a 15 week n-3 PUFA-deficient diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Membrane docosahexaenoate is supplied to the developing brain and retina by the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Lipid signaling in neural plasticity, brain repair, and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Receptor-mediated activation of phospholipase A2 and arachidonic acid release in signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Serotonin stimulates phospholipase A2 and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositolphospholipid hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Imaging brain phospholipase A2 activation in awake rats in response to the 5-HT2A/2C agonist (+/-)2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

NMDA receptors activate the arachidonic acid cascade system in striatal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

D2 but not D1 dopamine receptor stimulation augments brain signaling involving arachidonic acid in unanesthetized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Chronic lithium administration potentiates brain arachidonic acid signaling at rest and during cholinergic activation in awake rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

A transduction pathway associated with receptors coupled to the inhibitory guanine nucleotide binding protein Gi that amplifies ATP-mediated arachidonic acid release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

The PPARalpha-leukotriene B4 pathway to inflammation control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Prostaglandin receptor site: evidence for an essential role in the action of luteinizing hormone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Arachidonic acid cascade and signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Antimanic therapies target brain arachidonic acid signaling: lessons learned about the regulation of brain fatty acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Group-specific assays that distinguish between the four major types of mammalian phospholipase A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Revised nomenclature for the mammalian long-chain acyl-CoA synthetase gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Why is carbon from some polyunsaturates extensively recycled into lipid synthesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Prostaglandins and leukotrienes: advances in eicosanoid biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Leukotrienes and lipoxins: structures, biosynthesis, and biological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Role of Ca2+-independent phospholipase A2 and n-3 polyunsaturated fatty acid docosahexaenoic acid in prostanoid production in brain: perspectives for protection in neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

n-3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Prostaglandin synthesis in rat brain astrocytes is under the control of the n-3 docosahexaenoic acid, released by group VIB calcium-independent phospholipase A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Resolution of inflammation: the beginning programs the end

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Haloperidol targets brain arachidonic acid signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Rapid high-energy microwave fixation is required to determine the anandamide (N-arachidonoylethanolamine) concentration of rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Relation between free fatty acid and acyl-CoA concentrations in rat brain following decapitation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Acyl-CoA synthetase activity links wild-type but not mutant alpha-synuclein to brain arachidonate metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Arachidonic acid incorporation and turnover is decreased in sympathetically denervated rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Brain incorporation of [1-11C]arachidonate in normocapnic and hypercapnic monkeys, measured with positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Imaging signal transduction via arachidonic acid in the human brain during visual stimulation, by means of positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Brain incorporation of [11C]arachidonic acid in young healthy humans measured with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Half-lives of docosahexaenoic acid in rat brain phospholipids are prolonged by 15 weeks of nutritional deprivation of n-3 polyunsaturated fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

The low density lipoprotein receptor is not necessary for maintaining mouse brain polyunsaturated fatty acid concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Analysis of gene expression with cDNA microarrays in rat brain after 7 and 42 days of oral lithium administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Dynamics of docosahexaenoic acid metabolism in the central nervous system: lack of effect of chronic lithium treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

The effect of chronic lithium on arachidonic acid release and metabolism in rat brain does not involve secretory phospholipase A2 or lipoxygenase/cytochrome P450 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Decrease in the AP-2 DNA-binding activity and in the protein expression of AP-2 alpha and AP-2 beta in frontal cortex of rats treated with lithium for 6 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Transcription factor AP-2 mediates induction by two different signal-transduction pathways: protein kinase C and cAMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Isolation and characterization of the epsilon subspecies of protein kinase C from rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Chronic administration of carbamazepine down-regulates AP-2 DNA-binding activity and AP-2alpha protein expression in rat frontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Chronic valproate does not alter the kinetics of docosahexaenoic acid within brain phospholipids of the unanesthetized rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Elevated PLA2 activity in schizophrenics and other psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Allelic association study between phospholipase A2 genes and bipolar affective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Are disturbances in lipid-protein interactions by phospholipase-A2 a predisposing factor in affective illness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Evidence for a role of the arachidonic acid cascade in affective disorders: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Serum calcium-independent phospholipase A2 activity in bipolar affective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Elevated levels of prostaglandin E2 and thromboxane B2 in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Functional coupling between secretory phospholipase A2 and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Cytosolic prostaglandin E2 synthase (cPGES) expression is decreased in discrete cortical regions in psychiatric disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Lithium chloride, administered chronically to rats, does not affect the fractional phosphorylation of brain cytosolic phospholipase A2, while reducing its net protein level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Increase in AP-1 transcription factor DNA binding activity by valproic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Omega-3 fatty acids in psychiatry: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Omega-3 fatty acids and bipolar disorder: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Comparison of bloodstream fatty acid composition from African-American women at gestation, delivery, and postpartum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Polyunsaturated fatty acid deficit in patients with bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Chronic carbamazepine administration reduces N-methyl-D-aspartate receptor-initiated signaling via arachidonic acid in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A2 and its transcription factor, activator protein-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Chronic N-methyl-D-aspartate administration increases the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Chronic lithium chloride administration to unanesthetized rats attenuates brain dopamine D2-like receptor-initiated signaling via arachidonic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Chronic lithium administration to rats selectively modifies 5-HT2A/2C receptor-mediated brain signaling via arachidonic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Signaling: cellular insights into the pathophysiology of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Chronic treatment with mood stabilizers increases membrane GRK3 in rat frontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

In vivo imaging detects a transient increase in brain arachidonic acid metabolism: a potential marker of neuroinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Rat brain arachidonic acid metabolism is increased by a 6-day intracerebral ventricular infusion of bacterial lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Chronic lithium administration attenuates up-regulated brain arachidonic acid metabolism in a rat model of neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Immunologic variables in acute mania of bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Cytokine profiles in bipolar affective disorder: focus on acutely ill patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

One generation of n-3 polyunsaturated fatty acid deprivation increases depression and aggression test scores in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Dietary n-3 PUFA deprivation alters expression of enzymes of the arachidonic and docosahexaenoic acid cascades in rat frontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Role of arachidonic acid metabolism on corticotropin-releasing factor (CRF)-release induced by interleukin-1 from superfused rat hypothalami

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Requirement of thymus-dependent lymphocytes for potentiation by adjuvants of antibody formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Is aspirin, as used for antithrombosis, an emotion-modulating agent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Synthesis and activity of 2-oxoamides containing long chain beta-amino acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Inhibiting long chain fatty Acyl CoA synthetase increases basal and agonist-stimulated NO synthesis in endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Characterization of recombinant long-chain rat acyl-CoA synthetase isoforms 3 and 6: identification of a novel variant of isoform 6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

A pilot study of topiramate as monotherapy in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Effect of topiramate on body weight and body composition of osborne-mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Topiramate does not alter the kinetics of arachidonic or docosahexaenoic acid in brain phospholipids of the unanesthetized rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Chronic lamotrigine does not alter the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat: implications for the treatment of bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Antidepressants in bipolar disorder: the case for caution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Antidepressant treatment in bipolar versus unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Chronic fluoxetine increases cytosolic phospholipase A(2) activity and arachidonic acid turnover in brain phospholipids of the unanesthetized rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

CSF Prostaglandin Levels in Depressed and Schizophrenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

Fatty acyl-CoA thioesters are ligands of hepatic nuclear factor-4α

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

https://api.crossref.org/works/10.1038%2FMP.2008.31

1 reference

7 January 2021

Getting balance: drugs for bipolar disorder share target

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Therapeutic drug monitoring for the treatment of psychiatric disorders. Clinical use and cost effectiveness

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Essential fatty acids

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

A quantitative method for measuring regional in vivo fatty-acid incorporation into and turnover within brain phospholipids: review and critical analysis

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

The emerging role of group VI calcium-independent phospholipase A2 in releasing docosahexaenoic acid from brain phospholipids

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Arecoline-Stimulated Brain Incorporation of Intravenously Administered Fatty Acids in Unanesthetized Rats

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Valproic acid down‐regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase‐1 and ‐2 in rat brain

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

The effects of valproate on the arachidonic acid metabolism of rat brain microvessels and of platelets

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-kappaB DNA binding activity and COX-2 mRNA

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Genetic association between alleles of pancreatic phospholipase A2 gene and bipolar affective disorder

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Mutational analysis of phospholipase A2A: a positional candidate susceptibility gene for bipolar disorder

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Directly quantitated dietary (n-3) fatty acid intakes of pregnant Canadian women are lower than current dietary recommendations

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Bilobalide, a constituent of Ginkgo biloba, inhibits NMDA-induced phospholipase A2 activation and phospholipid breakdown in rat hippocampus

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

In Vivo D2 Dopamine Receptor Density in Psychotic and Nonpsychotic Patients With Bipolar Disorder

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Reduced Brain Inositol in Lithium-treated Rats

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Chronic administration of lamotrigine downregulates COX-2 mRNA and protein in rat frontal cortex

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline.

1 reference

https://api.crossref.org/works/10.1038%2FMP.2008.31

7 January 2021

Identifiers

DOI

10.1038/MP.2008.31

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference